Daix (France), Long Island City (New York, United States), July 21, 2022 – Inventiva (EuronextParisandNasdaq:IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here